XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%

MT Newswires Live

2025/08/06

XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.

Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.

Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.

DoveTree will hold exclusive global rights to develop and commercialize any resulting products.

XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557134474"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557134474\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2557134474?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-06 12:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557134474","market":"fut","top_or_hot":-1,"title":"XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%","media":"MT Newswires Live","content":"<html><body><p> XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.</p><p>Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.</p><p>DoveTree will hold exclusive global rights to develop and commercialize any resulting products.</p><p>XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXtalPi Finalizes Drug Discovery Agreement With DoveTree; Shares Surge 8%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-06 12:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree <a href=\"https://laohu8.com/S/MDCO\">Medicines</a> to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.</p><p>Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.</p><p>Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.</p><p>DoveTree will hold exclusive global rights to develop and commercialize any resulting products.</p><p>XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2557134474","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557134474","pubTimestamp":1754452929,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"XtalPi Holdings  finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.DoveTree will hold exclusive global rights to develop and commercialize any resulting products.XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","BK1617":"AI医疗","02228":"晶泰控股"},"translate_title":"XtalPi与DoveTree敲定药物发现协议；股价飙升8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02228":0.9},"content_text":"XtalPi Holdings (HKG:2228) finalized a definitive agreement with DoveTree Medicines to provide AI-driven drug discovery services, according to a Tuesday Hong Kong bourse filing.Shares of the bio-tech platform were up 8% in late-morning Wednesday trade.Through its wholly owned unit Shenzhen XtalPi, the company will use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas.DoveTree will hold exclusive global rights to develop and commercialize any resulting products.XtalPi has received an upfront payment of $51 million and expects to receive an additional $49 million. It is also eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales, the filing said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}